Cancer stem cells play an important role in development and progression of many cancer types including prostate adenocarcinoma. We used a stem cell marker CD44 to evaluate the prevalence of prostate cancer stem cells in prostate biopsies and in matched radical prostatectomy specimens. We tested both types of specimen for the existence of a correlation between the immunohistochemical expression of CD44 and Gleason grade, pathological stage (pT) according to TNM, patient age and preoperative plasma PSA levels in 52 pa tients. We found a positive correlation between the expression of CD44 in cancer cells from prostate biopsies and in matched radical prostatectomy specimens. We also observed that higher level of CD44 expression in cancer cells correlated with lower Gleason score, both in prostate biopsies and in radical prostatectomies. To the best of our knowledge we showed for the first time, that the level of CD44 expression in prostate biopsies correlates with that observed in matched radical prostatectomy specimens. Since the level of CD44 expression was shown to predict a response to anti cancer therapy in several types of human tumors, CD44 assess ment might support a clinical decision making process in prostate cancer patients.
Introduction
Prostate cancer is one of the leading causes of death among male oncology patients [1, 2] . Despite efforts aimed at the early detection and radical treat ment of prostate adenocarcinoma, the results remain unsatisfactory. After the initial response to treatment, prostate tumors relapse, usually in the more aggres sive form of hormonerefractory/castrationresistant cancer [3, 4] .
There is growing evidence supporting the hypoth esis that prostate cancer cells originate from stem cells [5, 6] . To date, however, no study has proven the cancer stem cell (CSC) theory to be true in terms of prostate cancer development and progression [7] . Additionally, there is no agreement as to which mark ers are most sensitive to stem cells. Among the most often used markers are CD44, CD133 and ALDH1 [810] .
In our preliminary assessment study that was per formed on a smaller number of samples, CD44 ex pression was found to have a tendency to correlate with some of the clinical variables. Due to this reason, as well as to the fact that previously published studies on CD44 showed discrepancies between the obtained results, we decided to address these issues. We used CD44 as one of the most promising putative stem cell markers to evaluate the prevalence of prostate cancer cells with stem celllike features in prostate biopsies and in radical prostatectomy material. We tried to find a correlation between the expression of CD44 in both types of tissues and widely used pros tate cancer prognostic factors such as Gleason grade, pathological stage according to TNM, the age of the patient and the preoperative plasma prostatespecific antigen (PSA) level. To the best of our knowledge, this is the first study in which this kind of approach has been used.
Material and methods
Formalinfixed, paraffinembedded (FFPE) tissue samples from 52 consecutive prostate biopsies and matched radical prostatectomy specimens from the years 2008 to 2011 were retrieved from the archives of the Pathology Department of the City Hospital in Poznan, Poland, or from a collection of cases sent for consultation in the private laboratory of one of the authors (JB). Only cases with accompanying ba sic clinical data were included in the study. Patient characteristics are shown in Table I .
Sections were cut from all the prostate biopsy specimens containing adenocarcinoma, and the re sulting slides were subsequently stained by immu nohistochemistry, using a primary antiCD44 anti body (monoclonal, MRQ13, CellMarque, Rocklin, CA, USA) according to the manufacturer's protocol. In the case of radical prostatectomy material, two paraffin blocks containing the most representative Gleason pattern were used for the same procedure. At least 100 cancer cells (in core biopsies) or 500 can cer cells (in radical prostatectomy specimens) were counted using an OLYMPUS BX41 microscope. Only those cells with clearly visible membranous staining, at 10× magnification, were called positive for the expression of CD44. The percentage of cancer cells expressing CD44 was recorded and used in fur ther analysis.
Statistical analysis was performed in Microsoft Of fice Excel 2007 using Spearman and Pearson correla tions. A P value < 0.05 was considered significant.
Results
Fortythree prostate biopsies (82%) and 47 rad ical prostatectomy specimens (90%) contained CD44positive cancer cells ( Figs. 1 and 2 ). The main observation during the assessment of the expression of CD44 was heterogeneity in terms of the percent age of positively stained cancer cells, both in the pros tate biopsies and in the radical prostatectomy materi al. The level of CD44 expression in prostate biopsies varied from 1% to 100% of cancer cells. However, in 31 cases (60%), the expression of CD44 did not ex ceed 30%. In radical prostatectomy specimens, CD44 expression was observed in 1% to 90% of cancer cells. As with the results seen in prostate biopsies, in the majority of radical prostatectomy cases (n = 33, Table I . Clinicopathologic findings of patients
Age, median (range)
63 (5072) PSA, median (ng/ml) 10.5
Gleason score (biopsies) n (%)
4-6
28 (53.8)
7-8 24 (46.2)
Gleason score (prostatectomies) n (%) 
Discussion
The adhesion molecule CD44 has been identified as a stem cell marker in prostate cancer [6, 8, 1114] (Table II) . It is a transmembrane receptor for hyaluro nan, which plays an important role in celltocell and celltomatrix adhesion, migration, signaling, and tumor metastasis. There is growing evidence show ing that CD44 is one of the most selective markers for cells presenting the features of stem cells. In his seminal work, Liu characterized prostate cancer cells in terms of CD44 expression [8] . Subsequently, Col lins et al. studied the expression of three markers -CD44, α(1)β(2)integrin and CD133 -on cancer cells isolated from prostate tumors [6] . The results of their work and that of other researchers showed that cells expressing CD44 were capable of selfrenewal and unlimited growth -characteristic features of stem cells [13, 15] .
In one of the earliest studies, by Zhang et al., per formed on FFPE tissue, CD44 expression was evalu ated in prostate cancer tissue samples obtained from 16 patients [16] . To date, there have been several other studies in which FFPE material was used to as sess CD44 expression in prostate cancer tumors, the largest study being that of Kallakury et al., which encompassed 106 patients [17] . The percentage of cases classified as positive, in terms of CD44 expres sion, was variable between the studies and ranged from 18% in the work by Eaton et al. up to 80% in the study by De Marzo et al. [18, 19] . This was prob ably due to differing, sometimes complicated criteria applied for the assessment of immunohistochemistry reactions. In our work, we tried to use the most ob jective rules by evaluating the percentage of cancer cells with clearly visible membranous staining at 10x magnification. This type of approach resulted in findings where 82% of prostate biopsies and 90% of radical prostatectomy specimens were found to con The most important question we addressed in our study concerned the ability to predict tumor grade and stage on the basis of CD44 expression in the cancer cells of prostate biopsies. Since there is growing evidence to indicate that the level of CD44 expression may have an impact on response to ad juvant therapies, that is radio and chemotherapies applied in several types of human cancers, awareness of CD44 expression levels could help to stratify pros tate cancer patients into groups of different progno sis, depending on the probability of clinical response [2023] . The data from our study showed a statis tically significant negative correlation between the expression of CD44 in the cancer cells of prostate biopsies and Gleason score, assessed both in prostate biopsies and in tumor specimens from radical pros tatectomy. Several other researchers have observed the same negative correlation in patients with pros tate cancer after radical prostatectomy [17, 19, 24] . However, only one study, by Zhang et al., reported a positive correlation between these two parameters, though the number of cases in their study was very low, comprising just 11 cases [16] . Other authors have found no correlation between CD44 expression and Gleason score [12, 15, 18, 25] . Since the meth odology used in the cited papers is not consistent, it might be a source of the discrepancies and makes the direct comparison between different studies dif ficult.
The following question arises on the basis of our and aforementioned studies: is CD44 a marker of true CSCs, or is it only a marker of differentiation between normal and malignant cells? Since we and other groups have observed lost CD44 expression in prostate cancers with higher Gleason scores, indicat ing a lower level of cancer cell differentiation, CD44 could be treated as a differentiation marker only. Liu, however, found that CD44expressing cancer cells from prostate cancer cell lines metastasize readily in animal models [8] . Liu also pointed out the ability of those cells to recognize the cells in high endothelial venules present in lymph nodes and bone marrow, a feature that allows them to form metastatic foci in such sites. Paradis et al. showed that the ability of CD44expressing prostate cancer cells to invade the surrounding tissue and to metastasize could depend on the role of the CD44 molecule as a receptor for hy aluronan, an extracellular matrix component which may participate in the process of invasion [15] . Ad ditionally, Tang et al. observed the inhibition of tu mor growth and metastases in mice inoculated with prostate cancer cells from a cell culture treated with miRNA 34a, which blocks CD44 expression in these cells [26] .
One possible explanation for these observations is that cancer cells expressing CD44 and other stem cell markers, such as ALDH1 and CD133, represent a subpopulation of cells with stemlike features, and with high proliferative and metastatic potential. In the primary site, these cells give rise to primary lowgrade prostate carcinomas, which subsequently dedifferentiate to highgrade cancer by losing CD44 expression. Meanwhile, stem cell like cancer cells ex pressing CD44 could invade the vascular system and metastasize to other organs. In two recent papers, re searchers found loss of standard CD44 form (CD44s) expression during prostate cancer progression [27, 28] . This concept should be further evaluated in comprehensive animal models and in studies of stem cell markers' expression in primary and metastatic prostate cancers.
Conclusions
In conclusion, CD44, as a putative stem cell mark er, plays an important role in prostate cancer develop ment and progression. To the best of our knowledge, the present study showed for the first time that the level of CD44 expression in prostate biopsies cor relates positively with its expression and negatively with the Gleason score in matched radical prostatec tomy specimens from prostate cancer patients. Addi tionally, we confirm the results of other authors which show that the percentage of CD44expressing cancer cells in prostate biopsies negatively correlates with the Gleason grade of tumors, both in prostate biopsies and in radical prostatectomy material. This informa tion also provides a rationale for the recognition of CD44 as a surrogate marker of tumor differentiation. Taken together, these results imply that by assessing CD44 expression in prostate biopsies, one may pre dict the level of CD44 expression in radical prosta tectomy specimens. This information could be very helpful for clinical oncologists, since there is growing evidence that CD44, together with other putative stem cell markers, plays an important role in predict ing response to cancer therapy. The importance of our findings warrants further prospective studies.
